N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: A pilot trial

Clinical Chemistry

Volumn 54, Issue 7, 2008, Pages 1149-1157

  Brune, Kay ^a   Katus, Hugo A ^b   Moecks, Joachim ^c   Spanuth, Eberhard ^c   Jaffe, Allan S ^d,e   Giannitsis, Evangelos ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c DIAneering GmbH   (Germany)

^d MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; RO 1130830;

ACUTE HEART INFARCTION; ADULT; ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; EDEMA; HAND OSTEOARTHRITIS; HEART BUNDLE BRANCH BLOCK; HEART FAILURE; HUMAN; HYPERTENSION; KNEE OSTEOARTHRITIS; LOW DRUG DOSE; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OSTEOARTHRITIS; PATIENT MONITORING; PREDICTOR VARIABLE; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; METALLOPROTEASES; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OSTEOARTHRITIS; PEPTIDE FRAGMENTS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 47549083869     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.097428     Document Type: Article

References (34)

1. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366.
2. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al., for the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
3. American College of Rheumatology. Hotline Web page. www.rheumatology.org/ publications/hotline/ 0305NSAIDs.asp (Accessed April 22, 2008).
4. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al., for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
5. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352: 1081-91.
6. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al., for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343: 1520-8.
7. Singh G, Mithal A, Triadafilopoulos G. Both inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not with the drug class [abstract]. In: European Congress of Rheumatology annual meeting program; 2005 June 8-11; Vienna, Austria. Abstract OP0091.
8. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al., on behalf of the TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
9. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-42.
10. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactve aminoterminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment. Clin Endocrinol 1997;47:287-96.
11. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrandt P, Dargie HJ. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail 2004;6:269-73.
12. Seino Y, Ogawa A, Yamashita T, Fuhushima M, Ogata K, Fukumoto H, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 2004; 6:295-300.
13. Svendstrup-Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 2004;6:63-70.
14. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004;341:41-8.
15. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic heart failure: a substudy of the Carvedilol Prospective Randomised Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110:1780-6.
16. Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF, Maggioni AP, et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004;110:128-34.
17. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.
18. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352: 666-75.
19. De Sutter J, De Bacquer D, Cuypers S, Delanghe J, De Buyzere M, Kornitzer M, De Backer M. Plasma N-terminal pro-brain natriuretic peptide concentration predicts coronary events in men at work: a report from the BELSTRESS study. Eur Heart J 2005;26:2644-9.
20. Barnes SC, Collinson PO, Galasko G, Senior R. Evaluation of N-terminal pro-B type natriuretic peptide analysis an the Elecsys 1010 and 2010 analyzers. Ann Clin Biochem 2004;41: 459-63.
21. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 2005;95:948-54.
22. Rabausch K, Bretschneider E, Sarbia M, Meyer-Kirchrath J, Censarek P, Pape R, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prosta-glandins. Circ Res 2005;96:e1-6.
23. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539-41.
24. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygen-ase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
25. Cipollone F, Fazia M, Mezzetti A. Novel determinants of plaque instability. J Thromb Haemost 2005;3:1962-75.
26. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7.
27. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum 2003;48:12-20.
28. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001;281:F1-11.
29. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002;32:33-42.
30. Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002;72:50-61.
31. Anderson F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113:1950-7.
32. Giannitsis E. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP. Clin Lab 2005; 51:63-72.
33. Blankfield RP. Can natriuretic peptide levels predict the cardiovascular complications of COX-2 inhibitors and nonsteroidal anti-inflammatory drugs? J Am Board Fam Med 2006;19:178-82.
34. Wu AH. Serial testing of B-type natriuretic peptide and NTproBNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006;152: 828-34.